Teva Receives Favorable Court Decision For Generic Prevacid SoluTab

Teva Pharmaceutical has reported that the US District Court for the District of Delaware has issued a decision in its litigation over the company’s Abbreviated New Drug Application (ANDA) to market its generic version of Takeda’s Prevacid (Lansoprazole) SoluTab.

The Court found that Teva’s generic Lansoprazole orally disintegrating tablets do not infringe US Patent No 5464632. Teva intends to complete an analysis of the decision before deciding upon its next course of action.

Teva Pharmaceutical receives FDA approval for generic version of heartburn drug Prevacid delayed release capsules.

Prevacid (Lansoprazole) is a medication that has been licensed to treat a number of conditions, including gastroesophageal reflux disease (GERD), erosive esophagitis, helicobacter pylori (H pylori) infections, pathological hypersecretory conditions (such as Zollinger-Ellison syndrome), stomach ulcers and duodenal ulcers.

Teva will sell 15mg and 30mg delayed-release capsule versions of the drug.